Latest Biguanides Stories
SAN DIEGO, May 20, 2013 /PRNewswire/ -- Enrollment of patients with Type 2 diabetes is underway in Elcelyx Therapeutics' Phase 2b dose-finding clinical trial of product candidate NewMet(TM), a delayed-release formulation of generic metformin, the foundational treatment for Type 2 diabetes. Elcelyx expects to complete enrollment of 240 patients in the multicenter U.S. program in June. Results of the trial's primary endpoint of change in fasting plasma glucose are expected in late...
Drug manufacturer did not submit suitable data in its dossier The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products” (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this fixed combination product offers an added benefit...
PITTSBURGH, March 13, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with Shionogi Inc. and Andrx that will resolve patent litigation related to Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg. This product is the generic version of Shionogi's Fortamet(®), and is indicated as an adjunct to diet and exercise to lower blood glucose.(1) Under the terms of the...
CORAL SPRINGS, Florida, January 31, 2013 /PRNewswire/ -- Crown Marketing Pharmaceuticals (OTC: CWNM [http://finance.yahoo.com/q?s=cwnm&ql=1 ]) announced today that it has achieved positive in-vitro testing results of the most widely prescribed Diabetes drug commonly known as Metformin. Crown's Controlled Drug Delivery Device (CDDT) is less than half the size of the 500mg dosage tablet, and may reduce and ameliorate many of the gastrointestinal side effects of Metformin....
Watch the video "Diabetes Drug Could Hold Promise For Lung Cancer Patients" Brett Smith for redOrbit.com - Your Universe Online Scientists have been enthusiastic about the potential use of widely available diabetes drugs to treat various types of cancer. A new study from The Salk Institute for Biological Studies and the David Geffen UCLA School of Medicine suggests that these metabolism-affecting drugs can decrease the size of lung tumors in mice and increase their chances for...
redOrbit Staff & Wire Reports - Your Universe Online Metformin, the drug most frequently prescribed by doctors to treat Type 2 Diabetes, works differently than previously believed -- a discovery which could lead to new treatments that have fewer side effects. Lead researcher Dr. Morris J. Birnbaum, a professor at the University of Pennsylvania's Institute for Diabetes, Obesity, and Metabolism (IDOM), and an international team of scientists have discovered that, in mice, metformin...
Lee Rannals for redOrbit.com – Your Universe Online A common diabetes medication could help in preventing or treating ovarian cancer, according to research published in the journal CANCER. The study found that ovarian cancer patients who took the drug tended to live longer than those patients who did not take it. Previous research showed that metformin, which originated from the French Lilac plant, might have anticancer properties. In the new study, the researchers analyzed...
